A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab
2007

Infliximab Prevents Bone Loss in Rheumatoid Arthritis Patients

Sample size: 189 publication 10 minutes Evidence: moderate

Author Information

Author(s): Marotte Hubert, Pallot-Prades Beatrice, Grange Laurent, Gaudin Philippe, Alexandre Christian, Miossec Pierre

Primary Institution: Hospices Civils de Lyon

Hypothesis

Does infliximab treatment prevent loss of bone mineral density in patients with rheumatoid arthritis?

Conclusion

Infliximab therapy prevents bone loss in rheumatoid arthritis patients, even in those who do not respond clinically.

Supporting Evidence

  • Bone mineral density decreased in the control group but remained stable in the infliximab group.
  • Infliximab treatment showed no significant change in bone turnover markers over one year.
  • 64% of infliximab patients were classified as good responders based on clinical improvement.

Takeaway

This study shows that a medicine called infliximab helps keep bones strong in people with rheumatoid arthritis, even if they don't feel better.

Methodology

A case-control study comparing bone mineral density changes in RA patients treated with infliximab versus a historical control group treated with methotrexate.

Potential Biases

Potential bias due to the non-randomized design and reliance on historical controls.

Limitations

The study used historical controls, which may not fully account for all confounding factors.

Participant Demographics

The study included 189 RA patients, with 152 women and 37 men, average age 52.5 years.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.01

Digital Object Identifier (DOI)

10.1186/ar2219

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication